Ensartinib

The FDA approved ensartinib for the treatment of certain patients with ALK-positive locally advanced or metastatic non-small cell lung cancer.

Ensartinib significantly increased PFS compared with crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer, according to an interim analysis of the phase 3, open-label eXalt3 study.